Search company, investor...

Founded Year



Series B | Alive

Total Raised


Last Raised

$27.72M | 1 yr ago

About KACTUS Biosystems

KACTUS Biosystems specializes in the production of recombinant proteins and enzymes for the biotechnology and pharmaceutical industries. The company offers a wide range of products including cell therapy proteins, gene editing reagents, and GMP-grade RNA enzymes, all designed to support drug development and diagnostic applications. KACTUS Biosystems also provides custom protein expression services tailored to specific research and clinical needs. It was founded in 2018 and is based in Shanghai, Shanghai.

Headquarters Location

4th Floor, Area 8A, No. 188 Xinjun Ring Road, Pujiang High-tech Park

Shanghai, Shanghai,





Latest KACTUS Biosystems News

Orgel's Conwood project seeks additional incentives for $61M phase

Mar 3, 2021

The developers are seeking a 20-year, $19 million payment-in-lieu-of-taxes (PILOT) for the $61 million, six-story phase at 47 Keel Ave.

KACTUS Biosystems Frequently Asked Questions (FAQ)

  • When was KACTUS Biosystems founded?

    KACTUS Biosystems was founded in 2018.

  • Where is KACTUS Biosystems's headquarters?

    KACTUS Biosystems's headquarters is located at 4th Floor, Area 8A, No. 188 Xinjun Ring Road, Pujiang High-tech Park, Shanghai.

  • What is KACTUS Biosystems's latest funding round?

    KACTUS Biosystems's latest funding round is Series B.

  • How much did KACTUS Biosystems raise?

    KACTUS Biosystems raised a total of $38.9M.

  • Who are the investors of KACTUS Biosystems?

    Investors of KACTUS Biosystems include New Alliance Capital, Lingang Lanwan Fund, Guofang Investment, Abon, Divine Capital and 7 more.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.